Drugs / sodium polystyrene sulfonate
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | KAYEXALATE | — | 1958-06-05 | fda.gov ↗ |
Trials 1
195719581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT04585542 | Oct 2020 → Jan 2025 | — | University of California, Irvine | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy4 trials | ||||||
| Phase 4 | NCT02065076 Comparator | Feb → Sep 2014 | chronic renal failure syndrome | Maisonneuve-Rosemont Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01866709 Comparator | May → Jul 2013 | — | ZS Pharma, Inc. | Terminated | No outcome recorded |
| — | NCT06029179 Comparator | Jan → Oct 2024 | — | Alexandria University | Completed | No outcome recorded |
| — | NCT06218212 Comparator | Feb 2022 → Mar 2023 | acute kidney injury | Ain Shams University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium polystyrene sulfonate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01866709 ↗ |
| Known as | SPS | “Sodium zirconium cyclosilicate (SZC) and sodium polystyrene sulfonate (SPS) for treatment of hyperkalemia in HD patients.” PMID 40329202 ↗ May 20251“Sodium Polystyrene Sulfonate Oral Suspension [SPS]” NCT04585542 ↗ |
| Modality | Other / unclassified | “potassium binding resins, such as sodium polystyrene sulfonate (SPS), patiromer, and sodium zirconium cyclosilicate.” NCT06029179 ↗ |
| Route | Oral | “Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.” NCT01866709 ↗ |